T Suter
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2010; 22:80-5.
01.07.2010Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
01.07.2010Ann Oncol 2010; 22:80-5
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober Jens, Spirig C, Lerch S, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis
Suter T, Malipiero U, Otten L, Ludewig B, Muelethaler-Mottet A, Mach B, Reith W, Fontana A. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. European journal of immunology 2000; 30:794-802.
01.03.2000Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis
01.03.2000European journal of immunology 2000; 30:794-802
Suter T, Malipiero U, Otten L, Ludewig Burkhard, Muelethaler-Mottet A, Mach B, Reith W, Fontana A